4th International Conference on Medical Imaging with Deep Learning Jul 07, 2021 - Jul 09, 2021 — Virtual Meeting (online)
Medical Image Understanding and Analysis Conference 2021 Jul 12, 2021 - Jul 14, 2021 — Virtual Meeting (online)
Medical Imaging Convention [rescheduled] Sep 15, 2021 - Sep 16, 2021 — National Exhibition Centre, Birmingham, England
2021 SINAPSE ASM Sep 16, 2021 - Sep 17, 2021 — Technology & Innovation Centre, University of Strathclyde, 99 George Street, Glasgow
Total Body PET 2021 conference [rescheduled] Sep 22, 2021 - Sep 24, 2021 — Virtual Meeting (online)

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Dr David Brennan

Position:

Interests:

David Brennan is a Principal Clinical Physicist at the Queen Elizabeth University Hospital in Glasgow. He has significant experience in the technology and clinical applications of Magnetic Resonance Imaging (MRI) and in image analysis. He runs a number of clinical services including, presurgical functional MRI and epilepsy image analysis services. David also provides clinical research services to a number of different research and clinical departments, including neurosurgery, neurology, neuropsychology, psychology and neurophysiology.

As well as academic qualifications David also holds a number of professional qualifications including MIPEM, CSci and is registered with the Health Professions Council as a State Registered Scientist.

David also works as Director of Project Management for Aurum Biosciences Ltd. Aurum develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.

Institute: Insitute of Nerological Sciences, Southern General Hospital, Glasgow

Department: Dept of Clinical Physics and Bioengineering